FDA advisors enthusiastic about Novartis's oral MS drug
This article was originally published in Scrip
Executive Summary
Novartis won a strong endorsement for its first-in-class oral multiple sclerosis (MS) medication Gilenia (fingolimod) from the US FDA's advisory committee on peripheral and central nervous system drugs on 10 June.